Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load
Journal of Gastroenterology, Volume 47, No. 10, Year 2012
Notification
URL copied to clipboard!
Description
Background: This study explores pretreatment predictive factors for ultimate virological responses to pegylated interferon-α (1.5 μg/kg/week) and ribavirin (600-1000 mg/day) (PEG-IFN/RBV) combination therapy for patients infected with hepatitis C virus (HCV)-1b and a high viral load. Methods: A total of 75 patients underwent PEG-IFN/RBV combination therapy for 48 weeks. HCV amino acid (aa) substitutions in non-structural protein 5a, including those in the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region and the core regions, as well as the genetic variation (rs8099917) near the interleukin 28B (IL28B) gene (genotype TT) were analyzed. Results: Of the 75 patients, 49 % (37/75) achieved a sustained virological response (SVR), 27 % (20/75) showed relapse, and 24 % (18/75) showed null virological response (NVR). Multivariate logistic regression analysis identified IRRDR with 6 or more mutations (IRRDR ≥6) [odds ratio (OR) 11.906, p < 0.0001] and age <60 years (OR 0.228, p = 0.015) as significant determiners of SVR and IL28B minor (OR 14.618, p = 0.0019) and platelets <15 × 104/mm3 (OR 0.113, p = 0.0096) as significant determiners of NVR. A combination of IRRDR ≥6 and age <60 years improved SVR predictability (93.3 %), and that of IRRDR ≤5 and age ≥60 years improved non-SVR predictability (84.0 %). Similarly, a combination of IL28B minor and platelets <15 × 104/mm3 improved NVR predictability (85.7 %), and that of IL28B major and platelets ≥15 × 104/mm3 improved non-NVR (response) (97.1 %) predictability. Conclusion: IRRDR ≥6 and age <60 years were significantly associated with SVR. IL28B minor and platelets <15 × 10 4/mm3 were significantly associated with NVR. Certain combinations of these factors improved SVR and NVR predictability and could, therefore, be used to design therapeutic strategies. © 2012 Springer.
Authors & Co-Authors
Kim, Soo Ryang
Japan, Kobe
Kobe Asahi Hospital
El-Shamy, Ahmed M.
Japan, Kobe
Graduate School of Medicine
Egypt, Ismailia
Faculty of Veterinary Medicine
Imoto, Susumu
Japan, Kobe
Kobe Asahi Hospital
Kim, Ke Ih
Japan, Kobe
Kobe Asahi Hospital
Ide, Yoshihiro
Japan, Kobe
Graduate School of Medicine
Deng, Lin
Japan, Kobe
Graduate School of Medicine
Shoji, Ikuo
Japan, Kobe
Graduate School of Medicine
Tanaka, Yasuhito
Japan, Nagoya
Nagoya City University Graduate School of Medical Sciences
Hasegawa, Yutaka
Japan, Kobe
Kobe Pharmaceutical University
Ota, Mitsuhiro
Japan, Kobe
Kobe Pharmaceutical University
Hotta, Haku
Japan, Kobe
Graduate School of Medicine
Statistics
Citations: 16
Authors: 11
Affiliations: 5
Identifiers
Doi:
10.1007/s00535-012-0578-z
ISSN:
09441174
e-ISSN:
14355922
Research Areas
Genetics And Genomics
Infectious Diseases
Study Design
Case-Control Study
Study Approach
Quantitative